KR102018929B1 - (5-플루오로-2-메틸-3-퀴놀린-2-일메틸-인돌-1-일)-아세트산에스테르의 제조 방법 - Google Patents

(5-플루오로-2-메틸-3-퀴놀린-2-일메틸-인돌-1-일)-아세트산에스테르의 제조 방법 Download PDF

Info

Publication number
KR102018929B1
KR102018929B1 KR1020147017740A KR20147017740A KR102018929B1 KR 102018929 B1 KR102018929 B1 KR 102018929B1 KR 1020147017740 A KR1020147017740 A KR 1020147017740A KR 20147017740 A KR20147017740 A KR 20147017740A KR 102018929 B1 KR102018929 B1 KR 102018929B1
Authority
KR
South Korea
Prior art keywords
formula
compound
iii
reaction
alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020147017740A
Other languages
English (en)
Korean (ko)
Other versions
KR20140113927A (ko
Inventor
자끄 토넬
토니 핀투스
알랭 부르고스
Original Assignee
키에시 파르마슈티시 엣스. 피. 에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 키에시 파르마슈티시 엣스. 피. 에이. filed Critical 키에시 파르마슈티시 엣스. 피. 에이.
Publication of KR20140113927A publication Critical patent/KR20140113927A/ko
Application granted granted Critical
Publication of KR102018929B1 publication Critical patent/KR102018929B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020147017740A 2011-12-15 2012-12-14 (5-플루오로-2-메틸-3-퀴놀린-2-일메틸-인돌-1-일)-아세트산에스테르의 제조 방법 Expired - Fee Related KR102018929B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201121557A GB201121557D0 (en) 2011-12-15 2011-12-15 Process
GB1121557.1 2011-12-15
PCT/GB2012/000903 WO2013088108A1 (en) 2011-12-15 2012-12-14 Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid esters

Publications (2)

Publication Number Publication Date
KR20140113927A KR20140113927A (ko) 2014-09-25
KR102018929B1 true KR102018929B1 (ko) 2019-09-05

Family

ID=45560499

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147017740A Expired - Fee Related KR102018929B1 (ko) 2011-12-15 2012-12-14 (5-플루오로-2-메틸-3-퀴놀린-2-일메틸-인돌-1-일)-아세트산에스테르의 제조 방법

Country Status (27)

Country Link
US (1) US9102658B2 (enExample)
EP (1) EP2791129B1 (enExample)
JP (2) JP6300277B2 (enExample)
KR (1) KR102018929B1 (enExample)
CN (1) CN104114548B (enExample)
AU (1) AU2012351341B2 (enExample)
BR (1) BR112014014604B1 (enExample)
CA (1) CA2859281C (enExample)
CY (1) CY1117087T1 (enExample)
DK (1) DK2791129T3 (enExample)
EA (1) EA026617B1 (enExample)
ES (1) ES2557762T3 (enExample)
GB (1) GB201121557D0 (enExample)
HR (1) HRP20151422T1 (enExample)
HU (1) HUE028257T2 (enExample)
IL (1) IL233132A (enExample)
ME (1) ME02348B (enExample)
MX (1) MX342273B (enExample)
PL (1) PL2791129T3 (enExample)
PT (1) PT2791129E (enExample)
RS (1) RS54523B1 (enExample)
SG (1) SG11201402798RA (enExample)
SI (1) SI2791129T1 (enExample)
SM (1) SMT201500327B (enExample)
UA (1) UA111868C2 (enExample)
WO (1) WO2013088108A1 (enExample)
ZA (1) ZA201404246B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201103837D0 (en) 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
GB201121557D0 (en) * 2011-12-15 2012-01-25 Oxagen Ltd Process
GB201322273D0 (en) * 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
EP3902794A1 (en) 2018-12-27 2021-11-03 Chiesi Farmaceutici S.p.A. Process for preparing spherical agglomerates of timapiprant
CN111978245A (zh) * 2020-09-15 2020-11-24 上海毕得医药科技有限公司 一种3-氟-2-异丁基吡啶的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006092579A1 (en) 2005-03-01 2006-09-08 Oxagen Limited Microcrystalline ( 5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1675826A1 (en) 2003-10-14 2006-07-05 Oxagen Limited Compounds having crth2 antagonist activity
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
GB0505048D0 (en) 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
US7188489B2 (en) 2005-04-12 2007-03-13 Martello Russell A Portable air conditioner
GB0605743D0 (en) * 2006-03-22 2006-05-03 Oxagen Ltd Salts with CRTH2 antagonist activity
EP2046740B1 (en) 2006-07-22 2012-05-23 Oxagen Limited Compounds having crth2 antagonist activity
US20110124683A1 (en) 2007-11-13 2011-05-26 Oxagen Limited Use of CRTH2 Antagonist Compounds
NZ587251A (en) 2008-01-18 2011-12-22 Oxagen Ltd Indole derivatives having CRTH2 antagonist activity
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
WO2009093026A1 (en) 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
EP2240444A1 (en) 2008-01-22 2010-10-20 Oxagen Limited Compounds having crth2 antagonist activity
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
GB201103837D0 (en) 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
GB201121557D0 (en) 2011-12-15 2012-01-25 Oxagen Ltd Process
WO2013088109A1 (en) 2011-12-16 2013-06-20 Oxagen Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006092579A1 (en) 2005-03-01 2006-09-08 Oxagen Limited Microcrystalline ( 5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) acetic acid

Also Published As

Publication number Publication date
US20140350264A1 (en) 2014-11-27
CY1117087T1 (el) 2017-04-05
WO2013088108A1 (en) 2013-06-20
CA2859281A1 (en) 2013-06-20
PL2791129T3 (pl) 2016-05-31
KR20140113927A (ko) 2014-09-25
IL233132A0 (en) 2014-08-03
ZA201404246B (en) 2016-10-26
BR112014014604A2 (pt) 2017-06-13
MX342273B (es) 2016-09-21
EP2791129B1 (en) 2015-10-07
GB201121557D0 (en) 2012-01-25
HRP20151422T1 (hr) 2016-02-26
CA2859281C (en) 2020-10-27
ME02348B (me) 2016-06-20
ES2557762T3 (es) 2016-01-28
MX2014007129A (es) 2014-09-04
DK2791129T3 (en) 2015-12-14
JP2018008985A (ja) 2018-01-18
AU2012351341A1 (en) 2014-07-24
SI2791129T1 (sl) 2016-02-29
RS54523B1 (sr) 2016-06-30
SMT201500327B (it) 2016-02-25
CN104114548B (zh) 2016-01-20
BR112014014604B1 (pt) 2021-01-12
EA026617B1 (ru) 2017-04-28
JP6300277B2 (ja) 2018-03-28
UA111868C2 (uk) 2016-06-24
HK1197671A1 (zh) 2015-02-06
PT2791129E (pt) 2016-01-26
JP2015500325A (ja) 2015-01-05
SG11201402798RA (en) 2014-06-27
IL233132A (en) 2015-09-24
HUE028257T2 (en) 2016-12-28
US9102658B2 (en) 2015-08-11
AU2012351341B2 (en) 2017-08-24
EP2791129A1 (en) 2014-10-22
CN104114548A (zh) 2014-10-22
NZ626732A (en) 2015-09-25
EA201490998A1 (ru) 2014-11-28

Similar Documents

Publication Publication Date Title
KR102018929B1 (ko) (5-플루오로-2-메틸-3-퀴놀린-2-일메틸-인돌-1-일)-아세트산에스테르의 제조 방법
EP2768807B1 (en) Processes for the preparation of 6-chloro-2,3,4,9-tetrahydro-1h-carbazole-1-carboxamide and of its precursors
EP1136470B1 (en) Process for the preparation of a piperazine derivative
KR20090119828A (ko) 4,4´-(1-메틸-1,2-에탄디일)-비스-(2,6-피페라진디온)의 신규 제조 방법
AU730383B2 (en) Process for preparing eprosartan
WO2009074333A1 (en) Synthesis of paliperidone
US9475799B1 (en) Synthesis of Raltegravir
CA3097628A1 (en) Intermediates and processes for the preparation of linagliptin and its salts
US9611217B2 (en) Synthetic processes of carprofen
NO330042B1 (no) Fremgangsmate til fremstilling av sure salter av gemifloksasin og mellomprodukt for fremstilling av samme.
EP3092222B1 (en) Improved fingolimod process
EP0748803B1 (en) Process for producing carboxylic acid derivative
US20120259116A1 (en) Novel Process for the Preparation of Paliperidone
HK1197671B (en) Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid esters
WO2015177801A1 (en) Novel process for the preparation of a lactam-containing compound
NZ626732B2 (en) Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid esters
CZ20001012A3 (cs) Imidazopyridinové deriváty a způsob jejich přípravy

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20220831

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20220831